MYX mayne pharma group limited

Nexstllis growth 267% units sold 256330 units sold, page-3

  1. 1,060 Posts.
    lightbulb Created with Sketch. 86
    NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales momentum building. Dispensed cycles were up 2.5x July 2023 v July 2022 and up 80% in 2HFY23 vs 1HFY23 attributable to the positive impact of our refreshed leadership and marketing strategy.2 days ago

    More than 3 fold revenue growth proves the company strategy success , with 75% reduction in marketing costs YOY , with the same rate , FY24 could reach 45 m to 50 Mil THEN so yes they are on the path to profitability . all indictors are positive .

    Share price outlook , if after the feb update that was 97 m worse the price reached 4.9 then after the +ve update expect 6 to 7 to 8.85 as per gauldman schs analysts
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.28
Change
0.030(0.57%)
Mkt cap ! $426.5M
Open High Low Value Volume
$5.25 $5.30 $5.25 $15.14K 2.867K

Buyers (Bids)

No. Vol. Price($)
3 782 $5.27
 

Sellers (Offers)

Price($) Vol. No.
$5.28 382 3
View Market Depth
Last trade - 10.13am 28/07/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.